Japanese drugmaker Shionogi & Co. (4507) has found a new way to cut costs: It now refuses to hire anyone with experience for vacant pharmaceutical sales rep positions. Tens of thousands of drug reps have lost their jobs through mass layoffs in the last three years, so Shionogi's "no-reps" policy will be especially insulting to American salespersons looking for new employment. The pay is also humiliating: $40,000 to $41,000 a year (although there's a $17,000 bonus on offer). Generally, U.S. drug rep salaries hover nearer to the $100,000 range.
Shionogi is little-known in the U.S. but grew its operations here when it acquired Sciele Pharma and its 920 staffers, most of whom are pharmaceutical sales reps. The company has co-marketing deals on Claritin and Crestor, and is developing new antibiotics with GlaxoSmithKline (GSK)
If you want to work for Shionogi in Staten Island, N.Y., however, this is the key qualification:
- YOU MUST NOT HAVE ANY PREVIOUS PHARMACEUTICAL SALES
Shionogi's move is a third new way that pharmaceutical managers have found to cut costs. Layoffs are the usual method, and AstraZeneca (AZN) recently replaced part of its Nexium sales force with a telemarketing center.
To play devil's advocate for a moment: Why shouldn't management start reining in sales rep salaries? As reps themselves have argued repeatedly in court, their job consists almost entirely of strictly repeating a script given to them by management when they meet with doctors. How much experience could that possibly require?
- Overtime Lawsuit at Bristol-Myers Will Infuriate Big Pharma Managers
- Death of a Salesman: AstraZeneca Replaced Entire Nexium Salesforce With Telemarketers -- and It Worked
Hat tip to Pharmalot.